TT
The startup develops targeted therapeutic agents that inhibit metabolic processes in cancer cells, leading to cell death while sparing normal cells. This approach specifically aims to improve treatment outcomes for patients with pancreatic ductal adenocarcinoma and other aggressive solid tumors.
Updated 3 months ago
Funding
$920K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops targeted therapeutic agents that inhibit metabolic processes in cancer cells, leading to cell death while sparing normal cells. This approach specifically aims to improve treatment outcomes for patients with pancreatic ductal adenocarcinoma and other aggressive solid tumors.